Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 3/20 | 0.50 |
| ▸ | MMP8 | P22894 | 3/20 | 0.50 |
| ▸ | MMP14 | P50281 | 1/20 | 0.50 |
| ▸ | PYGL | P06737 | 11/20 | 0.45 |
| ▸ | MMP3 | P08254 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL836791 | 0.73 | CAPN1 (0.38) | MMP9MMP8MMP14MMP3 | |
| SCHEMBL12225561 | 0.72 | MMP9 (0.66) | MMP9MMP8MMP14PYGLMMP3 | |
| SCHEMBL7064976 | 0.72 | MMP9 (0.66) | MMP9MMP8MMP14PYGLMMP3 | |
| SCHEMBL6319141 | 0.72 | MMP9 (0.66) | MMP9MMP8MMP14PYGLMMP3 | |
| SCHEMBL836084 | 0.72 | MMP1 (0.42) | MMP9MMP8MMP14MMP3 | |
| SCHEMBL863187 | 0.72 | ELANE (0.46) | — | |
| SCHEMBL25410860 | 0.71 | MMP9 (0.73) | MMP9MMP8MMP14PYGLMMP3 | |
| SCHEMBL15387081 | 0.71 | MMP9 (0.64) | MMP9MMP8MMP14PYGLMMP3 | |
| SCHEMBL24414099 | 0.71 | MMP9 (0.73) | MMP9MMP8MMP14PYGLMMP3 | |
| SCHEMBL16252286 | 0.70 | MMP9 (0.62) | MMP9MMP8MMP14PYGLMMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143375-B2 | Aziridine aldehydes, aziridine-conjugated amino derivatives, aziridine-conjugated biomolecules and processes for their preparation | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2012-03-27 | — | — | US | disclosed |
| US-8143375-B2 | Aziridine aldehydes, aziridine-conjugated amino derivatives, aziridine-conjugated biomolecules and processes for their preparation | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2012-03-27 | — | — | US | disclosed |
| US-20100317832-A1 | AZIRIDINE ALDEHYDES, AZIRIDINE-CONJUGATED AMINO DERIVATIVES, AZIRIDINE-CONJUGATED BIOMOLECULES AND PROCESSES FOR THEIR PREPARATION | ZEALAND PHARMA A/S (DK) | 2010-12-16 | — | — | US | disclosed |
| US-20100317832-A1 | AZIRIDINE ALDEHYDES, AZIRIDINE-CONJUGATED AMINO DERIVATIVES, AZIRIDINE-CONJUGATED BIOMOLECULES AND PROCESSES FOR THEIR PREPARATION | ZEALAND PHARMA A/S (DK) | 2010-12-16 | — | — | US | disclosed |
| WO-2008046232-A1 | AZIRIDINE ALDEHYDES, AZIRIDINE-CONJUGATED AMINO DERIVATIVES, AZIRIDINE-CONJUGATED BIOMOLECULES AND PROCESSES FOR THEIR PREPARATION | YUDIN ANDREI K (CA) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317832-A1 | AZIRIDINE ALDEHYDES, AZIRIDINE-CONJUGATED AMINO DERIVATIVES, AZIRIDINE-CONJUGATED BIOMOLECULES AND PROCESSES FOR THEIR PREPARATION | QDPR, VIP, AAAS | MMP9 1615/4885MMP8 2812/4885MMP14 4195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.